Firazorexton (INNTooltip International Nonproprietary Name; development code TAK-994) is an experimental orexin 2 (OX2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company.

[1][2] Firazorexton was studied by Takeda for the treatment of narcolepsy.

[3][4][5] It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) with >700-fold selectivity over the orexin receptor 1 (OX1).

[8] The compound reached phase 2 clinical trials for narcolepsy.

[9] However, clinical development was discontinued in October 2021 for safety reasons.